Dr. Clay Siegall: How a Couple Reacted to the Uncertainty in the Affordable Care Act

Home / Dr. Clay Siegall: How a Couple Reacted to the Uncertainty in the Affordable Care Act

 

Don Boyer and Anne are a couple from Yonkers, New York. They decided to get married in a rush due to the uncertainty in the Affordable Care Act brought about by President Trump’s administration. Anne has preexisting medical conditions, such as Vitamin B-12 malabsorption, several allergies, osteoporosis, and she has been seeking healthcare under Affordable Care Act. This act allows private insurers to accept everyone and does not discriminate people with preexisting conditions.

Boyer and Anne opted to be married so that when the Republican government makes changes to the healthcare system, she will be safe, and covered under her husband’s health insurance. This couple hired a Jewish priest and asked their landlord and a radio reporter to be witnesses to their union. According to Anne, it is already difficult to find an employer that provides favorable insurance covers. With changes likely to happen under the Republican Health Care Plan, Anne and Boyer opted to tackle the challenges that they will encounter as a couple.

Dr. Siegall’s educational background and career

Dr. Clay Siegall is the chairperson, president, and senior partner at Seattle Genetics. Dr. Siegall is a qualified researcher with interests in cancer and their targeted therapies. Dr. Siegall is an alma mater of the University of Maryland and George Washington University. At the start of his career, he worked for the National Cancer Institute, National Institute of Health for four years. It was in this facility that he developed a passion for cancer research. He later joined Bristol-Myers Squibb Pharmaceutical Research Institute for six years. Dr. Siegall is a member of the boards of Alder Biopharmaceuticals, Washington Roundtable, and Ultragenyx Pharmaceuticals.

Dr. Siegall contributions to Seattle Genetics

Dr. Siegall started Seattle Genetics in 1998 and tailored the company to specialize in drug development practices, rigorous research, and scientific innovation. His company pioneers in the development of antibody-drug conjugates (ADC). Under his management, Seattle Genetics has secured approval from FDA for its first ADC drug, ADCETRIS®. Seattle Genetics works with companies such as Takeda Pharmaceutical Company. This partnership has facilitated marketing of ADCETRIS® to over 65 countries worldwide. Dr. Siegall has also enabled Seattle Genetics to enter into several strategic licensing for its ADC technology with firms, such as GlaxoSmithKline, AbbVie, Pfizer, and Genentech. These partnerships have contributed millions of dollars’ worth of revenue.